According to a commentary, this finding is a big disappointment and once more, as has been previously reported in several trials of colon, breast, and lung cancer, the efficacy of anti-angiogenic drugs as reported in stage IV tumours did not translate to a benefit in early-stage disease. It notes the investigators had postulated that increased numbers of patients achieving a response to therapy, as recorded with the addition of bevacizumab to chemotherapy in stage IV oesophagogastric adenocarcinoma, would translate into higher R0 resection rates and thereby into improved survival. It suggests that the researchers were perhaps overoptimistic 10 years ago (when the ST03 trial was designed) about the benefits of anti-angiogenesis in treating early-stage cancers. It concludes that “after several unsuccessful studies investigating targeted drugs, it is unlikely that more trials in biologically non-stratified populations of patients with oesophagogastric cancer will be designed.”